Intrinsic Subtypes and Androgen Receptor Gene Expression in Primary Breast Cancer. A Meta-Analysis

Cruz‐Tapias, Paola; Rubiano, Wilson; Rondón-Lagos, Milena; Villegas, Victoria Eugenia; Rangel, Nelson

doi:10.3390/biology10090834

Cited by 5 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings differ from the previous study in which AR expression was found to be associated with a lower histologic grade only in ER-positive breast cancer but not in ER-negative breast cancer [ 24 ]. In PAM50 defined intrinsic subtypes, the expression of AR in basal-like subtype was less than in luminal A and luminal B subtypes which is consistent with previous studies [ 7 , 25 , 26 ]. Additionally, the correlation between the expression of AR and ESR1 was only significant in luminal A and basal-like subtype but not in luminal B and HER2-enriched subtypes.…”

Section: Discussionsupporting

confidence: 90%

AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status

Long

You

Song

et al. 2022

IJMS

View full text Add to dashboard Cite

Androgen receptor (AR) expression is frequently observed in breast cancer, but its association with estrogen receptor (ER) expression in breast cancer remains unclear. This study analyzed the clinicopathological and molecular features associated with AR negativity in both ER-positive and ER-negative breast cancer, trying to elucidate the molecular correlation between AR and ER. Our results showed that AR negativity was associated with different clinicopathological characteristics and molecular features in ER-positive and ER-negative breast cancer. Moreover, AR-positive breast cancer has better clinicopathological features than AR-negative breast cancer, especially in the ER-negative subtype. These results suggest that the role of AR in ER-negative breast cancer is distinctive from that in ER-positive breast cancer.

show abstract

Section: Discussionsupporting

confidence: 90%

AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status

Long

You

Song

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…AR overexpression was prevalently observed in patients affected by less aggressive intrinsic molecular subtypes expressing either ER or PR and having a lower histological grade, such as Luminal A and B compared to Basal-like subtype. High AR mRNA levels can be defined as a prognostic biomarker for the detection of the less aggressive BC subtypes [ 48 ]. In the current study, the distinction of BC HER2+ in luminal and non-luminal showed that the lobular histotype is prevalent in luminal AR+ and AR− tumors compared to non-luminal subtypes.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes

et al. 2022

View full text Add to dashboard Cite

HER2+ breast cancer (BC) is an aggressive subtype representing a genetically and biologically heterogeneous group of tumors resulting in variable prognosis and treatment response to HER2-targeted therapies according to estrogen (ER) and progesterone receptor (PR) expression. The relationship with androgen receptors (AR), a member of the steroid hormone’s family, is unwell known in BC. The present study aims to evaluate the prognostic impact of AR expression in HER2+ BC subtypes. A total of 695 BCs were selected and reviewed, AR, ER, PR and HER2 expression in tumor cells were examined by immunohistochemical method, and the SISH method was used in case of HER2 with equivocal immunohistochemical score (2+). A high prevalence of AR expression (91.5%) in BC HER+ was observed, with minimal differences between luminal and non-luminal tumor. According to steroid receptor expression, tumors were classified in four subgroups, including BC luminal and non-luminal HER2+ expressing or not AR. The luminal BC HER2 + AR+ was associated with lower histological grade, lower tumor size, higher PR expression and lower HER2 intensity of expression (2+). Also, the non-luminal tumors AR+ showed lower tumor size and lower prognostic stage but frequently higher grade and higher HER2 intensity of expression (3+). These findings should suggest a different progression of luminal and non-luminal tumors, both expressing AR, and allow us to speculate that the molecular mechanisms of AR, involved in the biology of BC HER2 + AR+, differ in relation to ER and PR expression. Moreover, AR expression may be a useful predictor of prognosis for overall survival (OS) in HER2+ BC subtypes. Our findings suggest that AR expression evaluation in clinical practice could be utilized in clinical oncology to establish different aggressiveness in BC HER2+ subtypes.

show abstract

“…Currently, a classification of five surrogate intrinsic subtypes is more commonly used in clinical practice; this classification is based on the assessment of ER, PR, HER2, and the proliferation marker Ki-67 ( 14 ). The histologic and molecular features of breast cancer are summarized in Figure 1 .…”

Section: Breast Cancer Biology and Classificationmentioning

confidence: 99%

“… The figure provides a schematic representation of surrogate intrinsic BC subtypes ( 14 ), based on histologic and molecular features, which have significant implication for prognosis and treatment choice. …”

Section: Breast Cancer Biology and Classificationmentioning

confidence: 99%

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Balma¹,

Liberini

Racca

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.

show abstract

Intrinsic Subtypes and Androgen Receptor Gene Expression in Primary Breast Cancer. A Meta-Analysis

Cited by 5 publications

References 64 publications

AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status

AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Contact Info

Product

Resources

About